Toronto, January 18, 2013 – Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), today made the following statement regarding today’s announcement by provincial governments on generic drug pricing:
“CGPA is pleased that provincial governments have decided not to proceed with tendering for generic pharmaceutical products. Tendering for generic drugs could result in drug shortages and delayed savings to Canada’s health-care system.
We are, however, disappointed by the provincial governments’ announcement of further cuts to retail or reimbursed prices for generic prescription medicines. Retail or reimbursed prices of generic prescription drugs have been dramatically reduced across Canada over the past few years. Some of these price reductions have not yet been fully implemented and the full impact not yet known.
We look forward to working with provincial governments and our partners in the pharmacist profession, community pharmacies and pharmacy distributors at the earliest possible opportunity to move forward with a formal collaborative process to increase access to care and achieve improved health outcomes for Canadians, while providing solutions to contain the rising costs of healthcare.”
About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada’s generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to fill 62 per cent of all prescriptions but account for
Jeff Connell Vice President, Corporate Affairs
Canadian Generic Pharmaceutical Association (CGPA)
Tel: (416) 223-2333
Mobile: (647) 274-3379